Piramal moves to commercialize amyloid tracer in Korea

Kathy Mahdoubi | | Health Imaging | Molecular Imaging

The PET amyloid imaging agent florbetaben F-18 may soon be available in South Korea as a result of a licensing agreement and partnership between producer Piramal Imaging and Ci-Co Healthcare, according to a Nov. 21 announcement from Piramal.

Ci-Co, as strategic partner and agent, will be charged with obtaining authorization to commercialize and market the radiotracer from the Korean Health Authorities. Manufacturing and supply are planned with South Korean radiopharmacy network DuChemBio.

"Piramal Imaging is committed to building a global presence in nuclear medicine and making florbetaben F-18 available to patients around the world. Ci-Co Healthcare shares Piramal Imaging's dedication and we look forward to a strong partnership that will allow both companies to achieve its goals," said Piramal board member Ludger Dinkelborg, in a release.

Kathy Mahdoubi

Related Content

Researchers receive grant worth millions to develop portable PET scanner
Why is the US still dependent on foreign medical isotope production?
Downed high-flux reactor could restart sooner than anticipated
Some nuc med departments are already feeling the strain of the isotope shortage
NorthStar opens facility to assist with development and distribution of vital radioisotopes
Lizard saliva could be key to spotting elusive pancreatic tumors

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.